Anaplastic Lymphoma Kinase Inhibitors Market

Market Insights

The anaplastic lymphoma kinase (ALK) inhibitors market is set to reach from US$ 1,496.4 million in 2018 to 8,329.1 million by 2027, keen to demonstrate exuberant growth at a compounded annual growth rate (CAGR) of 21.2% during the forecast period from 2019 to 2027. Lung cancer is the second most common type of cancer in both men and women worldwide. Increased consumption of tobacco, an unhealthy lifestyle, and stress are the major risk factors responsible for the occurrence of lung cancer. A strong pipeline of second and third-generation ALK inhibitors is currently being studied in various stages of clinical trials and is being developed specifically for the treatment of non-small cell lung cancer (NSCLC).

Market Synopsis

Excellent pharmacodynamic and pharmacokinetic properties drive the market growth of first-generation ALK inhibitors.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer occurring throughout the globe. The prognosis of NSCLC is difficult, and its initial screening is rather poor, which significantly increases the requirement for the development of targeted drug therapy for its treatment. The FDA has approved only 2 drugs specifically for the treatment of NSCLC.

In the present scenario, the first-generation ALK inhibitor Crizotinib is spearheading the molecule segment of the anaplastic lymphoma kinase inhibitor market. It is basically an aminopyridine and piperidine derivative that selectively inhibits receptor tyrosine kinase and the ALK fusion proteins during the treatment of NSCLC. It has the potency to inhibit tumor cell growth.

Alectinib hydrochloride is another first-line ALK inhibitor that effectively inhibits wild-type ALK point mutant variants and disrupts the tumor cell growth associated with advanced-stage NSCLC. Hence, excellent pharmacodynamic and pharmacokinetic properties together drive the market growth for first-generation ALK inhibitors.

Rising prevalence of lung cancer and an affordable reimbursement scenario together drive the market growth in the North American region.

North America, with a share of 36.2%, is currently leading the regional segment for anaplastic lymphoma kinase (ALK) inhibitors. According to the research findings of the American Society of Clinical Oncology (ASCO), in 2019, approximately 228,150 U.S. citizens have been reported to be suffering from lung cancer, with a high prevalence rate among African American people. Affordable reimbursement scenarios pertaining to the treatment of non-small cell lung cancer drive the market growth of ALK inhibitors in the North American region.

Europe is in second place with a 29.8% market share, primarily due to the huge prevalence rate of lung cancer in the European Union, which is 54 per 100,000 people, as brought forward by the 2018 statistical report of the European Commission. The supportive regulatory environment provided by the European Medical Agency expedites the clinical trials pertaining to second and third-generation anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC).

Asia Pacific presently accounts for 15.5% of the market share and is keen to register outstanding growth during the forecast period on account of a significant rise in tobacco consumption, thereby promoting the proliferation of NSCLC and developing healthcare infrastructure.

Historical and Forecast Period

This research report presents the analysis of each segment from 2017 to 2027, considering 2018as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

Biopharmaceutical companies actively seeking to create a strong foothold in the anaplastic lymphoma kinase inhibitor market are Betta Pharmaceuticals Co., Ltd., Crtierium, Inc., F. Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG, Oncoethix GmbH, Pfizer, Inc., Takeda Pharmaceutical Co., Ltd., Xcovery Holding Company, LLC, and Tesaro, Inc.

Key questions are answered in this report.

• Which biopharmaceutical companies are engaged in the development of ALK inhibitors for the treatment of NSCLC?
• What are the inorganic and organic market growth strategies adopted for the market assessment of the anaplastic lymphoma kinase inhibitor market?
• What is the disease etiology associated with NSCLC?
• Why are the first-line ALK inhibitors employed selectively for the treatment of NSCLC?
• What is the prevalence rate of lung cancer in developing nations in the Asia-Pacific and Latin America regional segments?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Molecule
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global ALKI Market Portraiture
2.2. Global ALKI Market, by Molecule, 2018 (US$ Mn)
2.3. Global ALKI Market, by Geography, 2018 (US$ Mn)

Chapter 3. Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global ALKI Market, by Key Players, 2018

Chapter 4. Global Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market, by Molecule
4.1. Overview
4.2. Crizotinib
4.3. Ceritniib
4.4. Alectinib hydrochloride
4.5. Pipeline Analysis
4.5.1. Tabular Representation of Phase I and II Drug Pipeline

Chapter 5. Global Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market, by Geography
5.1. Overview
5.2. North America ALKI Market Analysis, 2017 – 2027
5.2.1. North America ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
5.2.2. North America ALKI Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe ALKI Market Analysis, 2017– 2027
5.3.1. Europe ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
5.3.2. Europe ALKI Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific ALKI Market Analysis, 2017 – 2027
5.4.1. Asia Pacific ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific ALKI Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America ALKI Market Analysis, 2017 – 2027
5.5.1. Latin America ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
5.5.2. Latin America ALKI Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa ALKI Market Analysis, 2017 – 2027
5.6.1. MEA ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
5.6.2. MEA ALKI Market, by Region, 2017– 2027 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Betta Pharmaceuticals Co., Ltd.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Criterium, Inc.
6.3. F. Hoffman-La Roche Ltd.
6.4. Helsinn Therapeutics
6.5. Novartis AG
6.6. Oncoethix GmbH
6.7. Pfizer, Inc.
6.8. Takeda Pharmaceutical Co., Ltd.
6.9. Xcovery Holding Company, LLC
6.10. Tesaro, Inc.

List of Figures

FIG. 1 Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market: Research Methodology
FIG. 2 ALKI: Market Segmentation
FIG. 3 Global ALKI Market, by Molecule, 2018 (US$ Mn)
FIG. 4 Global ALKI Market, by Geography, 2018 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2018
FIG. 6 Competitive Analysis: Global ALKI Market, by Key Players, 2018
FIG. 7 Global Crizotinib Molecule Market for ALKI, 2017 – 2027 (US$ Mn)
FIG. 8 Global Ceritinib Molecule Market for ALKI, 2017 – 2027 (US$ Mn)
FIG. 9 Global Alectinib Hydrochloride Molecule Market for ALKI, 2017 – 2027 (US$ Mn)
FIG. 10 U.S. ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 11 Canada ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 12 U.K. ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 13 Germany ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 14 Rest of Europe ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 15 China ALKI Market, 2017– 2027 (US$ Mn)
FIG. 16 Japan ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 17 Rest of Asia Pacific ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 18 Brazil ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 19 Mexico ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 20 Rest of Latin America ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 21 GCC ALKI Market, 2017 – 2027 (US$ Mn)
FIG. 22 Rest of Middle East and Africa ALKI Market, 2017 – 2027 (US$ Mn)

List of Tables

TABLE 1 Global Anaplastic Lymphoma Kinase Inhibitors (ALKI) Market Portraiture
TABLE 2 Global ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
TABLE 3 Global ALKI Market, by Geography, 2017 – 2027 (US$ Mn)
TABLE 4 North America ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
TABLE 5 North America ALKI Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 6 Europe ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
TABLE 7 Europe ALKI Market, by Country/Region, 2017– 2027 (US$ Mn)
TABLE 8 Asia Pacific ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
TABLE 9 Asia Pacific ALKI Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Latin America ALKI Market, by Molecule, 2017 – 2027 (US$ Mn)
TABLE 11 Latin America ALKI Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 12 Middle East and Africa ALKI Market, by Molecule, 2017– 2027 (US$ Mn)
TABLE 13 Middle East and Africa ALKI Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 14 Betta Pharmaceuticals Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Criterium, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 F. Hoffman-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Helsinn Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Oncoethix GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Takeda Pharmaceutical Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Xcovery Holding Company, LLC.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Tesaro, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)